Skip to main content

Multisystem Cell Therapy for Improvement of Urinary Continence

Objective

"Stress Urinary Incontinence (SUI) is a disease affecting over 200 million people worldwide. It represents a condition with a prevalence of 20-50% in women, thereby creating an immense socio-economic burden. The currently available treatment strategies entail various complications and offer only short-term relief to the patients. Tissue engineering using autologous cells offers a feasible alternative for functional restoration of the damaged urinary sphincter muscle and represents an ideal treatment option that could reverse the underlying pathologic conditions.
MUSIC aims at translating basic knowledge on regenerative medicine (RM) and stem cell therapy into the clinic by undertaking a ""first-in-man"" multisystem study using autologous muscle precursor cells (MPCs) in a combination with neuromuscular electromagnetic stimulation (NMES) in 40 female patients. We will carry out the specific tasks to prove safety and efficacy of the proposed novel multilevel treatment as well as reproducibility of the therapeutic effect. Additional objectives are optimization of the advanced-therapy medicinal product (ATMP) towards totally xeno-free and facilitated manufacturing as well as the introduction of a novel injection technique for more efficient and precise implantation of the final product.
Combining expertise, MUSIC features a unique infrastructure, including the knowledge of experts in the fields of RM, urology, cellular biology and biomaterials throughout Europe (CH, NL, UK, A, D). The MUSIC consortium has an exclusive opportunity to determine the validity of this MPC cellular treatment in combination with NMES and to further improve its feasibility and clinical efficacy. The ultimate goal is to significantly improve the patients` quality of life and to exploit a future commercial opportunity by expanding the know-how to various smaller RM centers and companies within Europe, thus, making personalized medicine using autologous cells a more feasible SUI treatment option.


"

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/medical biotechnology/tissue engineering
  • /engineering and technology/industrial biotechnology/biomaterials
  • /medical and health sciences/clinical medicine/urology

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITAT ZURICH
Address
Ramistrasse 71
8006 Zurich
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 0

Participants (5)

KUROS BIOSCIENCES BV

Participation ended

Netherlands
EU contribution
€ 0
Address
Professor Bronkhorstlaan 10 G 48
3723 MB Bilthoven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
COLLAGEN SOLUTIONS (UK) LIMITED
United Kingdom
EU contribution
€ 562 197,50
Address
3 Robroyston Oval Nova Business Park
G33 1AP Glasgow
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG
Austria
EU contribution
€ 187 500
Address
Strubergasse 21
5020 Salzburg
Activity type
Higher or Secondary Education Establishments
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 575 223,75
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
SCINUS HOLDING BV
Netherlands
EU contribution
€ 1 024 600
Address
Professor Bronkhorstlaan 10 G 48
3723 MB Bilthoven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)